Tenax Therapeutics announces plan to develop levosimendan for a PAH indication
Tenax Therapeutics announced plans to advance the development of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction. PH-HFpEF is a common condition with a poor outcome (5 year survival less than 50%). January 16, 2018